☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
NCT02792699
Amgen and Allergan Report Results of ABP 798 (rituximab- biosimilar) in P-I/III (NCT02792699) for Moderate-To-Severe Rheumatoid Ar...
January 24, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.